4 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow IPH-2101: new trials by email Literature Review of IPH-2101 trials Research Report on IPH-2101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma IPH2101 - Smoldering Multiple Myeloma | Phase 2 | Completed | Innate Pharma | 30 | 2010-09-01 | 2026-05-14 |
| Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma IPH2101 - Multiple Myeloma | Phase 2 | Completed | Innate Pharma | 27 | 2009-09-01 | 2016-03-24 |
| An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma Anti-KIR (1-7F9) - Multiple Myeloma | Phase 1 | Completed | Innate Pharma | 32 | 2007-05-01 | 2016-03-31 |
| A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia IPH2101 - Acute Myeloid Leukemia | Phase 1 | Completed | Innate Pharma | 21 | 2007-02-01 | 2014-02-28 |
Multiple Myeloma (2) · Leukemia, Myeloid, Acute (1) · Smoldering Multiple Myeloma (1)
Innate Pharma (4)
France (2) · United States (2)
Don Benson, Jr., MD, PhD (1) · Nikhil Munshi, MD (1) · Norbert Vey, MD (1) · Sherif Farag, MD, PhD (1) · Sundar Jagannath, MD (1) · Swaminathan Padmanabhan, MD (1)